Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Randomized, Double-Blind, Placebo and Active Controlled, Multicenter, Parallel Group Proof of Concept Study of the Analgesic Effects of RN624 [tanezumab] in Adult Patients With Chronic Low Back Pain

Next Previous
X
Search
Trial Profile

Phase II Randomized, Double-Blind, Placebo and Active Controlled, Multicenter, Parallel Group Proof of Concept Study of the Analgesic Effects of RN624 [tanezumab] in Adult Patients With Chronic Low Back Pain

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tanezumab (Primary) ; Tanezumab (Primary) ; Naproxen
  • Indications Back pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 22 Dec 2022 Results of meta analysis (n=3414 from 3 studies NCT00584870,NCT00876187 and NCT02528253) assessing Different Dosage Regimens of Tanezumab for the Treatment of Chronic Low Back Pain published in the Clinical Neuropharmacology
    • 16 Oct 2008 Actual number of patients (225) added as reported by CT.gov
    • 02 Oct 2008 Status changed from recruiting to completed as reported by CT.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top